The present and future treatment of pediatric type 2 diabetes

References

• Jones KL, Arslanian S, Peterokova VA, et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002;25(1):89–94.
   PubMed Web of Science ®Google Scholar
• Today Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012; 366(24):2247–2256.
   PubMed Web of Science ®Google Scholar
• Herbst A, Kapellen T, Schober E, et al. Impact of regular physical activity on blood glucose control and cardiovascular risk factors in adolescents with type 2 diabetes mellitus – a multicenter study of 578 patients from 225 centres. Pediatr Diabetes. 2015;16(3):204–210.
   PubMed Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–1585.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Inagaki N. Metformin: new preparations and nonglycemic benefits. Curr Diab Rep. 2017;17(1):5.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016;101(4):1754–1761.
   PubMed Web of Science ®Google Scholar
• Niafar M, Hai F, Porhomayon J, et al. The role of metformin on vitamin B12 deficiency: a meta-analysis review. Intern Emerg Med. 2015;10(1):93–102.
   PubMed Web of Science ®Google Scholar
• Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab. 2013;98(1):322–329.
   PubMed Web of Science ®Google Scholar
• McDonagh MS, Selph S, Ozpinar A, et al. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014;168(2):178–184.
   PubMed Web of Science ®Google Scholar
• Libman IM, Miller KM, DiMeglio LA, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314(21):2241–2250.
   PubMed Web of Science ®Google Scholar
• Klingensmith GJ, Lanzinger S, Tamborlane WV, et al. Adolescent type 2 diabetes: comparing the pediatric diabetes consortium and Germany/Austria/Luxemburg pediatric diabetes prospective registries. Pediatr Diabetes. 2018. [Epub ahead of Print].
   Google Scholar
• Zeitler P, Fu J, Tandon N, et al. ISPAD clinical practice consensus guidelines 2014. Type 2 diabetes in the child and adolescent. Pediatr Diabetes. 2014;15(Suppl 20):26–46.
   PubMed Web of Science ®Google Scholar
• Lajara R, Cengiz E, Tanenberg RJ. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes. Curr Med Res Opin. 2017;33(6):1045–1055.
   PubMed Web of Science ®Google Scholar
• Bacha F, Cheng P, Gal RL, et al. Initial presentation of type 2 diabetes in adolescents predicts durability of successful treatment with metformin monotherapy: insights from the pediatric diabetes consortium T2D registry. Horm Res Paediatr. 2018;89(1):47–55.
   PubMed Web of Science ®Google Scholar
• Gregg B, Connor CG, Cheng P, et al. C-peptide levels in pediatric type 2 diabetes in the pediatric diabetes consortium T2D clinic registry. Pediatr Diabetes. 2016;17(4):274–280.
   PubMed Web of Science ®Google Scholar
• Nambam B, Silverstein J, Cheng P, et al. A cross-sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the pediatric diabetes consortium type 2 diabetes registry. Pediatr Diabetes. 2017;18(3):222-229.
   Web of Science ®Google Scholar
• Galderisi A, Sherr J, VanName M, et al. Pramlintide but not liraglutide suppresses meal-stimulated glucagon responses in type 1 diabetes. J Clin Endocrinol Metab. 2018;103(3):1088–1094.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–848.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Announcement NNC. Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide. 2018; cited 2018 Jul 5. Avaliable from: https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2170941.html
   Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Sherman SI, Bergenstal RM, et al. The safety of incretin-based therapies – review of the scientific evidence. J Clin Endocrinol Metab. 2011;96(7):2027–2031.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333–347.
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med. 2014;370(9):794–797.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076.
   PubMed Web of Science ®Google Scholar
• Gantz I, Chen M, Suryawanshi S, et al. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):112.
   PubMedGoogle Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Stamatouli AM, Inzucchi SE. Implications of the EMPA-REG trial for clinical care and research. Curr Diab Rep. 2016;16(12):131.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
   PubMed Web of Science ®Google Scholar
• Patel NS, Van Name MA, Cengiz E, et al. Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT2 inhibitor: an insulin pump suspension study. Diabetes Technol Ther. 2017;19(11):618–622.
   PubMed Web of Science ®Google Scholar
• Farrell R, Bethin K, Klingensmith G, et al. Barriers to participation in industry-sponsored clinical trials in pediatric type 2 diabetes. Pediatr Diabetes. 2017;18(7):574–578.
   PubMed Web of Science ®Google Scholar
• Today Study Group, Zeitler P, Epstein L, et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007;8(2):74–87.
   PubMed Web of Science ®Google Scholar